← Product Code [LPH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LPH) · K970300 # NATURAL-HIP SYSTEM POROUS STEM WITH HA/CSTI (K970300) _Intermedics Orthopedics · LPH · Jul 3, 1997 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LPH/K970300 ## Device Facts - **Applicant:** Intermedics Orthopedics - **Product Code:** [LPH](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LPH.md) - **Decision Date:** Jul 3, 1997 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3358 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The Natural-Hip System Porous Stem with HA/CSTi is intended to replace the anatomy of the femur in cases of total hip or hemi-hip replacement. In addition, the Natural-Hip System Porous Stem with HA/CSTi, like the predicate Intermedics Orthopedics, Inc. (IOI) and competitive hip stems, is intended for cementless (press-fit) application in cases of total hip or hemi-hip arthroplasty. The general indications associated with the use of the Natural-Hip System Porous Stem with HA/CSTi in total hip arthroplasty include: 1. Patient conditions of noninflammatory degenerative joint disease (NIDJD), e.g., avascular necrosis, osteoarthritis, and inflammatory joint disease (IJD), e.g., rheumatoid arthritis. 2. Those patients with failed previous surgery where pain, deformity, or dysfunction persists. 3. Revision of previously failed hip arthroplasty. Total hip replacements may be considered for younger patients if any unequivocal indication outweighs the risks associated with the age of the patient, and modified demands regarding activity and hip joint loading are assured. This includes severely crippled patients with multiple joint involvement, for whom an immediate need of hip mobility leads to an expectation of significant improvement in the quality of their lives. The Natural-Hip System Porous Stem with HA/CSTi is intended only for use without bone cement in the United States. This device is intended for single use only. ## Device Story Natural-Hip System Porous Stem with HA/CSTi is a femoral component for total or hemi-hip arthroplasty; designed for cementless (press-fit) fixation. Device features straight stem geometry with proximal anterior angulation/build-up and nine-degree anteversion to match femoral anatomy. Distal portion includes ribs, flutes for rotational stability, and flared coronal slot to reduce stiffness. Surface features circumferential hydroxylapatite (HA) coating over Cancellous Structured Titanium (CSTi) porous coating to facilitate biological fixation. Used by orthopedic surgeons in clinical/OR settings. Device replaces femoral anatomy; provides structural support for hip joint; restores mobility; reduces pain in patients with degenerative or inflammatory joint disease. Single-use device. ## Clinical Evidence No clinical data provided. Substantial equivalence is based on design and material characteristics. ## Technological Characteristics Material: Ti-6Al-4V alloy (ASTM F-136). Coating: Circumferential hydroxylapatite (HA) over Cancellous Structured Titanium (CSTi) porous coating. Design: Straight stem, collared/collarless options, proximal anterior angulation, 9-degree anteversion, distal ribs/flutes, flared coronal slot. Energy source: None (mechanical). Connectivity: None. Sterilization: Not specified. ## Regulatory Identification A hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis is a device intended to be implanted to replace a hip joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across the joint. This generic type of device has a femoral component made of a cobalt-chromium-molybdenum (Co-Cr-Mo) alloy or a titanium-aluminum-vanadium (Ti-6Al-4V) alloy and an acetabular component composed of an ultra-high molecular weight polyethylene articulating bearing surface fixed in a metal shell made of Co-Cr-Mo or Ti-6Al-4V. The femoral stem and acetabular shell have a porous coating made of, in the case of Co-Cr-Mo substrates, beads of the same alloy, and in the case of Ti-6Al-4V substrates, fibers of commercially pure titanium or Ti-6Al-4V alloy. The porous coating has a volume porosity between 30 and 70 percent, an average pore size between 100 and 1,000 microns, interconnecting porosity, and a porous coating thickness between 500 and 1,500 microns. The generic type of device has a design to achieve biological fixation to bone without the use of bone cement. ## Predicate Devices - Natural-Hip System Porous Stem (Intermedics Orthopedics, Inc.) - APR Universal Hip System with Calcitite®-Coated CSTi (Intermedics Orthopedics, Inc.) - Howmedica Precision Osteolock - Osteonics Omnifit with HA ## Reference Devices - IOI metallic femoral bearing heads ([K905781](/device/K905781.md), [K913060](/device/K913060.md)) - IOI Biolox Bearing Heads ([K923734](/device/K923734.md), [K942330](/device/K942330.md)) - Zirconia Bearing Heads ([K944209](/device/K944209.md)) - IOI bipolar components ([K833404](/device/K833404.md), [K873815](/device/K873815.md)) - IOI unipolar components ([K833403](/device/K833403.md), [K934159](/device/K934159.md)) - IOI acetabular components ([K850793](/device/K850793.md), [K920955](/device/K920955.md), [K933203](/device/K933203.md), [K942406](/device/K942406.md), [K941617](/device/K941617.md), [K954800](/device/K954800.md), [K955033](/device/K955033.md), [K955739](/device/K955739.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0} K970300 JUL - 3 1997 # 510(k) SUMMARY OF SAFETY AND EFFECTIVENESS In accordance with the Food and Drug Administration Rule to implement provisions of the Safe Medical Devices Act of 1990 and in conformance with 21 CFR 807, this is to serve as a Summary of Safety and Effectiveness for the Natural-Hip™ System Porous Stem with HA/CSTi™. Submitter: Intermedics Orthopedics, Inc. 9900 Spectrum Drive Austin, Texas 78717 (512) 432-9900 Date: January 20, 1997 Contact Person: Jacquelyn Hughes Manager, Regulatory Affairs Classification Name: Hip joint metal/polymer/metal semi-constrained porous-coated uncemented prosthesis, 21 CFR 888.3358. Common/Usual Name: Biologically fixed total hip prosthesis, semi-constrained Trade/Proprietary Name: Natural-Hip™ System Porous Stem with HA/CSTi™ # PRODUCT DESCRIPTION The Natural-Hip System Porous Stem with HA/CSTi is a straight stem manufactured from Ti-6Al-4V alloy conforming to ASTM F-136. The stem is available in both a collared and collarless design. The proximal anterior surface of the stem employs anterior angulation or build-up to match the anatomic angulation of a natural femur. The superior portion of the stem has a built-in anteversion of nine degrees to match the anatomic anteversion of the femur. Circumferential hydroxylapatite coated Cancellous Structured Titanium™ (CSTi™) porous coating provides biological fixation in a cementless application. The distal portion of the Natural-Hip System Porous Stem with HA/CSTi employs ribs and flutes on the anterior and posterior sides to enhance cortical contact, thereby providing rotational stability to the hip stem. In addition, the distal portion of the stem has a flared coronal slot which reduces stiffness of the stem. This device is intended for use with the following previously cleared devices: - IOI metallic femoral bearing heads (510(k)s K905781 and K913060), - IOI Biolox Bearing Heads (510(k)s K923734, K942330), - Zirconia Bearing Heads (510(k) K944209), - IOI bipolar components (510(k)s K833404 and K873815), - IOI unipolar components (510(k)s K833403 and K934159), 000786 {1} IOI acetabular components (510(k)s K850793, K920955, K933203, K942406, K941617, K954800, K955033 and K955739). # SPECIFIC DIAGNOSTIC INDICATIONS The Natural-Hip System Porous Stem with HA/CSTi is intended to replace the anatomy of the femur in cases of total hip or hemi-hip replacement. In addition, the Natural-Hip System Porous Stem with HA/CSTi, like the predicate Intermedics Orthopedics, Inc. (IOI) and competitive hip stems, is intended for cementless (press-fit) application in cases of total hip or hemi-hip arthroplasty. The general indications associated with the use of the Natural-Hip System Porous Stem with HA/CSTi in total hip arthroplasty include: 1. Patient conditions of noninflammatory degenerative joint disease (NIDJD), e.g., avascular necrosis, osteoarthritis, and inflammatory joint disease (IJD), e.g., rheumatoid arthritis. 2. Those patients with failed previous surgery where pain, deformity, or dysfunction persists. 3. Revision of previously failed hip arthroplasty Total hip replacements may be considered for younger patients if any unequivocal indication outweighs the risks associated with the age of the patient, and modified demands regarding activity and hip joint loading are assured. This includes severely crippled patients with multiple joint involvement, for whom an immediate need of hip mobility leads to an expectation of significant improvement in the quality of their lives. The Natural-Hip System Porous Stem with HA/CSTi is intended only for use without bone cement in the United States. This device is intended for single use only. # SUBSTANTIAL EQUIVALENCE The Natural-Hip System Porous Stem with HA/CSTi is substantially equivalent to the Natural-Hip System Porous Stem (Intermedics Orthopedics, Inc.), the APR Universal Hip System with Calcitite®-Coated CSTi (Intermedics Orthopedics, Inc.), the Howmedica Precision Osteolock, and the Osteonics Omnifit with HA. 000787 {2} DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Lori Kleinschrodt Holder, RAC Regulatory Affairs Specialist Sulzer Orthopedics Inc. 9900 Spectrum Drive Austin, Texas 78717 JUL 3 1997 Re: K970300 Natural-Hip™ System Porous Stem with HA/CSTi™ Regulatory Class: II Product Codes: LPH and MEH Dated: April 23, 1997 Received: April 25, 1997 Dear Ms. Holder: We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). This decision is based on consideration of the specific design of stem and coating composition detailed in this application. You may, therefore, market the device, subject to the general controls provisions of the Act and the following limitation: You may not label or in any way promote these devices for enhanced clinical or radiographic performance, enhanced biological fixation and/or long-term stable fixation. The data presented support equivalence with no additional claims over a conventional porous-coated uncemented hip prosthesis (i.e., biological fixation, only). Additional limitations for more specific claims of safety and effectiveness may be forthcoming. Should additional limitations be applied you will be contacted in writing to inform you of the additional labeling limitations. {3} Page 2 - Lori Kleinschrodt Holder, RAC The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. You may market your device under the above limitations as class II devices. These devices would be considered not substantially equivalent to a legally marketed predicate device if labeled with other intended uses and/or claims of safety or effectiveness. Any other intended uses or claims may cause the device to be classified into Class III under Section 513(f) of the Act. Class III devices are required to have an approved premarket approval (PMA) application prior to marketing. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal Laws or Regulations. This letter will allow you to begin marketing your device as described in your 510(k) premarket notification immediately. An FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on {4} Page 3 - Lori Kleinschrodt Holder, RAC the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html". Sincerely yours, ![img-0.jpeg](img-0.jpeg) Celia M. Witten, Ph.D., M.D. Director Division of General and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {5} Page 1 of 1 510(k) Number (if known): K970300 Device Name: Natural-Hip™ System Porous Stem with HA/CSTi™ ## Indications For Use: 1. Patient conditions of non-inflammatory degenerative joint disease (NIDJD), e.g., avascular necrosis, osteoarthritis and inflammatory joint disease (IJD), e.g., rheumatoid arthritis. 2. Those patients with failed previous surgery where pain, deformity, or dysfunction persists. 3. Revision of previously failed arthroplasty. The Natural-Hip™ System Porous Stem with HA/CSTi™ is intended only for use without bone cement. (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) ![img-1.jpeg](img-1.jpeg) (Division Sign-Off) Division of General Restorative Devices 510(k) Number K970300 Prescription Use ☑ OR Over-The-Counter Use ☐ (Optional Format 1-2-96) --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LPH/K970300](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LPH/K970300) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com